UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/536,533	11/29/2005 Ganga Prasad Rai		4544-051675	7482
28289 THE WEBB LA	7590 05/04/201 AW FIRM, P.C.	EXAMINER		
700 KOPPERS 436 SEVENTH	BUILDING	HINES, JANA A		
PITTSBURGH,	-		ART UNIT	PAPER NUMBER
			1645	
			NOTIFICATION DATE	DELIVERY MODE
			05/04/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@webblaw.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/536,533	RAI ET AL.		
Examiner	Art Unit		
JA'NA HINES	1645		

	JA'NA HINES	1645	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress
THE REPLY FILED <u>05 April 2011</u> FAILS TO PLACE THIS APPI	LICATION IN CONDITION FOR AL	LOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	eplies: (1) an amendment, affidavit al (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
 a) The period for reply expires 4 months from the mailing date b) The period for reply expires on: (1) the mailing date of this Acono event, however, will the statutory period for reply expire latexaminer Note: If box 1 is checked, check either box (a) or (IMONTHS OF THE FINAL REJECTION. See MPEP 706.07(f) 	dvisory Action, or (2) the date set forth it ter than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extrunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the size forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.13 ension and the corresponding amount of nortened statutory period for reply origin	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi AMENDMENTS	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett appeal; and/or (d) They present additional claims without canceling a content of the second c	sideration and/or search (see NOT v); er form for appeal by materially rec	E below);	
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be all non-allowable claim(s).	·		·
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows: Claim(s) allowed: None. Claim(s) objected to: None. Claim(s) rejected: 23-27. Claim(s) withdrawn from consideration: 28.		l be entered and an ex	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fails	s to provide a
10. \square The affidavit or other evidence is entered. An explanation	of the status of the claims after er	ntry is below or attach	ed.
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but	does NOT place the application in	condition for allowand	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (13. Other:	PTO/SB/08) Paper No(s)		
	/Mark Navarro/ Primary Examiner, Art U	nit 1645	

Continuation Sheet (PTO-303)

Application No.

The proposed after final amendment will not be entered. The proposed amendment filed after final rejection raises new issues that would require further consideration and/or search. Moreover, the proposed amendment is not deemed to place the application in better form for appeal by materially reducing or simplfying the issues for appeal.

Therefore claims 24-25 rejected under 103(a) as being Nilsson et al., in view of Sukosol et al., is maintained for reasons already of record in order to have an agglutination reagent for a more sensitive and specific detection.

Claims 23-24 and 26-27 are rejected under 103(a) as being unpatentable over Nllsson et al., Sukosol et al., Salzman et al., and Fruitstone et al., for the reasons already of record. The rejection was on the grounds t would have been prima facie obvious at the time of applicants' invention to apply the antibody specific to the flagellin gene of Salmonella typhi as taught by Sukosol et al., the preparation of the of the purified protein as taught by Salzman et al., and the storage buffers as taught by Fruitstone et al., to the method for the preparation of agglutination reagents as taught by Nilsson et al., in order to provide advantageously achieve for agglutination reagent used for diagnosis which overcomes disadvantages associated with agglutination test while providing highly selective and sensitive typhoid detection.